Evidence map›Paper›PMID 31602579›Full record

ArticleAnnals of surgical oncology2020

Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative.

Mohammad Y Zaidi, Rachel M Lee, Adriana C Gamboa, Shelby Speegle, Jordan M Cloyd, Charles Kimbrough, Travis Grotz, Jennifer Leiting, Keith Fournier, Andrew J Lee and 19 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022
    Article
  8. The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Review
  9. Peritoneal mesothelioma.Translational lung cancer research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Mohammad Y ZaidiDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road, NE; Building C, 2nd Floor, Atlanta, GA, 30322, USA.
Rachel M LeeDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road, NE; Building C, 2nd Floor, Atlanta, GA, 30322, USA.
Adriana C GamboaDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road, NE; Building C, 2nd Floor, Atlanta, GA, 30322, USA.
Shelby SpeegleDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road, NE; Building C, 2nd Floor, Atlanta, GA, 30322, USA.
Jordan M CloydDivision of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Charles KimbroughDivision of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Travis GrotzDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
Jennifer LeitingDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
Keith FournierDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew J LeeDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sean DineenDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Sophie DessureaultDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Kaitlyn J KellyDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, USA.
Nikhil V KothaDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, USA.
Callisia ClarkeDivision of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, USA.
T Clark GamblinDivision of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, USA.
Sameer H PatelDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Tiffany C LeeDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Ryan J HendrixDivision of Surgical Oncology, Department of Surgery, University of Massachusetts Medical School, Worcester, MA, USA.
Laura LambertSection of Surgical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Sean Ronnekleiv-KellyDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI, USA.
Courtney PokrzywaDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI, USA.
Andrew M BlakelyDivision of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Byrne LeeDivision of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Fabian M JohnstonDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Nadege FackcheDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Maria C RussellDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road, NE; Building C, 2nd Floor, Atlanta, GA, 30322, USA.
Shishir K MaithelDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road, NE; Building C, 2nd Floor, Atlanta, GA, 30322, USA.
Charles A StaleyDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road, NE; Building C, 2nd Floor, Atlanta, GA, 30322, USA. cstaley@emory.edu.

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378
6 · The paper itself

Abstract

backgroundFor patients with peritoneal carcinomatosis undergoing cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC), incomplete cytoreduction (CCR2/3) confers morbidity without survival benefit. The aim of this study is to identify preoperative factors which predict CCR2/3.

methodsAll patients who underwent curative-intent CRS/HIPEC of low/high-grade appendiceal, colorectal, or peritoneal mesothelioma cancers in the 12-institution US HIPEC Collaborative from 2000 to 2017 were included (n = 2027). The primary aim is to create an incomplete-cytoreduction risk score (ICRS) to predict CCR2/3 CRS utilizing preoperative data. ICRS was created from a randomly selected cohort of 50% of patients (derivation cohort) and verified on the remaining patients (validation cohort).

resultsWithin our derivation cohort (n = 998), histology was low-grade appendiceal neoplasms in 30%, high-grade appendiceal tumor in 41%, colorectal tumor in 22%, and peritoneal mesothelioma in 8%. CCR0/1 was achieved in 816 patients and CCR 2/3 in 116 patients. On multivariable analysis, preoperative factors associated with incomplete cytoreduction were male gender [odds ratio (OR) 3.4, p = 0.007], presence of ascites (OR 2.8, p = 0.028), cancer antigen (CA)-125 ≥ 40 U/mL (OR 3.4, p = 0.012), and carcinoembryonic antigen (CEA) ≥ 4.2 ng/mL (OR 3.2, p = 0.029). Each preoperative factor was assigned a score of 0 or 1 to form an ICRS from 0 to 4. Scores were grouped as zero (0), low (1-2), or high (3-4). Incidence of CCR2/3 progressively increased by risk group from 1.6% in zero to 13% in low and 39% in high. When ICRS was applied to the validation cohort (n = 1029), this relationship was maintained.

conclusionThe incomplete cytoreduction risk score incorporates preoperative factors to accurately stratify the risk of CCR2/3 resection in CRS/HIPEC. This score should not be used in isolation, however, to exclude patients from surgery.

Indexed as

AdultAgedAppendiceal NeoplasmsCohort StudiesColorectal NeoplasmsCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHumansHyperthermia, InducedMaleMesotheliomaMiddle AgedNeoplasms, Glandular and EpithelialPeritoneal NeoplasmsPredictive Value of Tests

Identifiers

PMID31602579
PMCPMC7195626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.